Alnylam authorizes new $1.00 billion stock buyback
Alnylam's board approved the program on Nov. 2, and the company expects to repurchase about $500 million of stock by the end of 2026.
Key takeaways
- Alnylam Pharmaceuticals (ALNY) authorized a stock repurchase program of up to $1.00 billion. The company expects to buy about $500 million of stock by the end of 2026 and the balance in 2027. The program has no expiration date. Chief Commercialization Officer Tolga Tanguler will depart in December 2026.
Alnylam Pharmaceuticals (ALNY) authorized a program to repurchase up to $1.00 billion of its common stock. The board approved the 2026 Repurchase Program on Nov. 2.
Shares fell 2.8% at 3:59 p.m. ET, from a $161.08 close.
Repurchases may be made from time to time in open market transactions, including under trading plans intended to qualify under Rule 10b5-1, or in privately negotiated transactions, in accordance with Rule 10b-18. The company expects to repurchase about $500 million of stock by the end of 2026, and the balance during 2027.
The timing and amount of purchases will depend on the market price of the stock, business and market conditions, liquidity and capital requirements, and other investment opportunities. The program has no expiration date and does not obligate Alnylam to repurchase any particular dollar amount or number of shares. It may be modified, suspended or discontinued at any time without prior notice.
Tolga Tanguler, Executive Vice President and Chief Commercialization Officer, will depart from his role in December 2026. Alnylam and Tanguler intend to enter into a written agreement no later than his separation date setting out the terms of his departure.